Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 11;136(8):902-919.
doi: 10.1161/CIRCRESAHA.124.323578. Epub 2025 Apr 10.

Pathways and Molecular Mechanisms Governing LDL Receptor Regulation

Heidi M Schmidt #  1 , Kelsey E Jarrett #  1 , Thomas Q de Aguiar Vallim  1   2   3   4 , Elizabeth J Tarling  1   3   4
Affiliations
Review

Pathways and Molecular Mechanisms Governing LDL Receptor Regulation

Heidi M Schmidt et al. Circ Res. .

Abstract

Clearance of circulating plasma LDL (low-density lipoprotein) cholesterol by the liver requires hepatic LDLR (low-density lipoprotein receptor). Complete absence of functional LDLR manifests in severe hypercholesterolemia and premature atherosclerotic cardiovascular disease. Since the discovery of the LDLR 50 years ago by Brown and Goldstein, all approved lipid-lowering medications have been aimed at increasing the abundance and availability of LDLR on the surface of hepatocytes to promote the removal of LDL particles from the circulation. As such a critical regulator of circulating and cellular cholesterol, it is not surprising that LDLR activity is tightly regulated. Despite over half a century's worth of study, there are still many facets of LDLR biology that remain unexplored. This review will focus on pathways that regulate the LDLR and emerging concepts of LDLR biology.

Keywords: cardiovascular diseases; cholesterol; lipoproteins; liver; receptors, LDL.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Galicia-Garcia U, Benito-Vicente A, Uribe KB, Jebari S, Larrea-Sebal A, Alonso-Estrada R, Aguilo-Arce J, Ostolaza H, Palacios L, Martin C. Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. Scientific reports. 2020;10(1):1727. doi:10.1038/s41598-020-58734-9 - DOI - PMC - PubMed
    1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47. doi:10.1126/science.3513311 - DOI - PubMed
    1. Banerjee P, Chan KC, Tarabocchia M, Benito-Vicente A, Alves AC, Uribe KB, Bourbon M, Skiba PJ, Pordy R, Gipe DA, Gaudet D, Martin C. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arterioscler Thromb Vasc Biol. 2019;39(11):2248–2260. doi:10.1161/ATVBAHA.119.313051 - DOI - PMC - PubMed
    1. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133–170. doi:10.1146/annurev.ge.24.120190.001025 - DOI - PubMed
    1. Stancu C, Sima A. Statins: mechanism of action and effects. J Cellular Molecular Medi. 2001;5(4):378–387. doi:10.1111/j.1582-4934.2001.tb00172.x - DOI - PMC - PubMed

LinkOut - more resources